Perrigo
This article was originally published in The Tan Sheet
Executive Summary
Two ANDA approvals expected "very shortly," with six to eight additional approvals likely in 12-15 months following private labeler's resolution of quality control problems cited in August warning letter, President & CEO David Gibbons says at UBS Warburg Global Specialty Pharmaceuticals Conference May 23. "We have recently been notified by the FDA that we have satisfactorily addressed the issues...and we are now able to get our ANDAs approved," Gibbons says. Perrigo has nine ANDAs pending with the agency; firm is eyeing near-term launches of private label Pepcid AC, Advil Cold & Sinus, Rogaine Extra Strength, Excedrin Migraine and NasalCrom
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning